Comparison of Pharmacokinetics and Bioavailability of Fixed‐Dose Combination Tablet and Monotherapy Combination of Allisartan Isoproxil and Indapamide Sustained‐Release in Healthy Chinese Volunteers

were 987 and 999 ng/mL, 8059 and 7749 ng/mL h, and 8332 and 8007 ng/mL h, respectively. The corresponding values for indapamide were 27 and 32 ng/mL, 1002 and 1105 ng/mL h, and 1080 and 1172 ng/mL h. No serious adverse events were reported during the study. The combination tablet containing 240 mg of AI and 1.5 mg of indapamide SR met the bioequivalence standards. Additionally, both formulations were tolerated and had good safety profiles in the research.